Synthesis of Fosfluconazole

Although fosfluconazole is some 25-fold less active than fluconazole in vitro, it is rapidly hydrolyzed by phosphatases in vivo and has similar efficacy in animal models and in patients, where it is 97% bioavailable (Hegde and Schmidt, 2005). The prodrug has a half-life of 2.3 h in patients, and the vast majority of the dose is excreted as fluconazole. Consequently, fosfluconazole has a similar clinical profile to that of fluconazole. 

Ballard, S. A., Ellis, S. W., Kelly, S. L., and Troke, P. F. (1990). Journal of medical and veterinary mycology bi-monthly publication of the International Society for Human and Animal Mycology, 28 335-344. 

USAN Nevirapine Trade name Viramune Boehringer ingelheim Launched 1996 M.W. 266.30 

USAN Efavirenz Trade name Susliva , Stocrin Bristoi-Myers Squibb/Merck Launched 1998 M.W. 315.67 

USAN Deiavirdine mesyiate V Trade name Rescriptot Pfizer 

---